We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

8 hedge funds and large institutions have $4K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.99% less ownership

Funds ownership: 4.99% → 0% (-5%)

80% less funds holding

Funds holding: 41 → 8 (-33)

94% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 35

100% less capital inflows, than outflows

Capital inflows: $996 | Capital outflows: $1.03M

Holders
8
Holders Change
-33
Holders Change %
-80.49%
% of All Funds
0.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
35
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$366K
2
Cormorant Asset Management
Cormorant Asset Management
Massachusetts
-$221K
3
SM
Sabby Management
Florida
-$107K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$81K
5
Renaissance Technologies
Renaissance Technologies
New York
-$80K

PVCT Hedge Fund Activity: Q4 2016 in Review

8 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2016, worth a combined $4K — down 100% from $1.05M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of PVCT and 2 opened new positions — a net loss of 33 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $366K sold.

  • 8 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2016, down from 41 in Q3 2016.
  • Funds reported $4K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2016, down 100% quarter-over-quarter.
  • 2 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2016 and 35 closed out, a net change of -33 holders.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2016 was Vanguard Group, an estimated $366K sold.

Based on aggregated 13F filings for Q4 2016.